JLJamie Lewis

Jamie Lewis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jamie Lewis has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Magnesium isotope heterogeneity in oceanic island basalts

    by Xiao-Ning Liu, Remco C. Hin, Christopher D. Coath, Isaac Onyett, Bryony Rogers, Jamie Lewis, Tim Elliott

  • Diet, cellular, and systemic homeostasis control the cycling of potassium stable isotopes in endothermic vertebrates

    by T Tacail, J Lewis, M Clauss, C D Coath, R Evershed, E Albalat, T R Elliott, T Tütken

    The naturally occurring stable isotopes of potassium (41K/39K, expressed as δ41K) have the potential to make significant contributions to vertebrate and human biology. The utility of K stable isotopes is however conditioned by the understanding of the dietary and biological factors controlling natural variability of δ41K. This paper reports a systematic study of K isotopes in extant terrestrial endothermic vertebrates. δ41K has been measured in 158 samples of tissues, biofluids and excreta from 40 individuals of four vertebrate species (rat, guinea pig, pig and quail) reared in two controlled feeding experiments. We show that biological processing of K by endothermic vertebrates produces remarkable intra-organism δ41K variations of ca. 1.6 ‰. Dietary δ41K is the primary control of interindividual variability and δ41K of bodily K is +0.5 to 0.6 ‰ higher than diet. Such a trophic isotope effect is expected to propagate throughout trophic chains, opening promising use for reconstructing dietary behaviours in vertebrate ecosystems. In individuals, cellular δ41K is related to the intensity of K cycling and effectors of K homeostasis, including plasma membrane permeability and electrical potential. Renal and intestinal transepithelial transports also control fractionation of K isotopes. Using a box-modelling approach, we establish a first model of K isotope homeostasis. We predict a strong sensitivity of δ41K to variations of intracellular and renal K cycling in normal and pathological contexts. Thus, K isotopes constitute a promising tool for the study of K dyshomeostasis.


  • Additive effect of sirolimus and anti‐death receptor 5 agonistic antibody against hepatocellular carcinoma

    by Toshiyasu Kawahara, Christian Toso, Keisuke Yamaguchi, Sonia Cader, Donna N. Douglas, Mahra Nourbakhsh, Jamie T. Lewis, Thomas A. Churchill, Hideo Yagita, Norman M. Kneteman

    Background & Aims: Despite careful patient selection, hepatocellular carcinoma (HCC) recurs in 10–20% of cases after liver transplantation, and the use of potent adjuvant anticancer drugs would be welcome. The aim of this study was to evaluate the efficiency of a combined therapy of rapamycin (sirolimus) and anti‐death receptor (DR)5 monoclonal antibody (mAb) on HCC.Methods: We first assessed the side effects of anti‐DR5 mAb administration in vivo by giving various doses of anti‐DR5 mAb. Cell proliferation assays were then performed using mouse Hepa1‐6 cells or human Huh7 cells to quantify the relative cell viability under various concentrations of sirolimus, anti‐DR5 mAb or a combination. Next, one million Hepa1‐6 cells were transplanted into C.B17‐SCID‐beige mice subcutaneously, and four groups were created: (1) untreated, (2) anti‐DR5 mAb alone, (3) sirolimus alone and (4) anti‐DR5 mAb + sirolimus.Results: Anti‐DR5 mAb (200 and 300 μg/day) induced liver dysfunction with partial necrosis of the liver, but 100 μg/day was well tolerated with transaminitis, but normal bilirubin and only minor histological liver damage. In vitro, anti‐DR5 mAb lysed Hepa1‐6 and Huh7 cells in a dose‐dependent manner, and combinations of sirolimus and anti‐DR5 mAb demonstrated an additive effect. In vivo studies demonstrated that tumour sizes were significantly smaller in the combined therapy group than in the monotherapy groups.Conclusions: Combining sirolimus and low‐dose anti‐DR5 mAb has a significant effect against HCC. This strategy represents a potential novel approach for the management of HCC.